Cargando…

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data

BACKGROUND: Iron plays a key role in human immune responses; however, the influence of iron deficiency on the coronavirus disease 2019 (COVID-19) vaccine effectiveness is unclear. AIM: To assess the effectiveness of the BNT162b2 messenger RNA COVID-19 vaccine in preventing severe acute respiratory s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tene, Lilac, Karasik, Avraham, Chodick, Gabriel, Pereira, Dora I. A., Schou, Henrik, Waechter, Sandra, Göhring, Udo-Michael, Drakesmith, Hal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202294/ https://www.ncbi.nlm.nih.gov/pubmed/37216375 http://dx.doi.org/10.1371/journal.pone.0285606

Ejemplares similares

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
por: Chodick, Gabriel, et al.
Publicado: (2021)

79. Long-term Health Outcomes of Individuals who are Infected with SARS-CoV-2 and Develop COVID-19
por: Tene, Lilac, et al.
Publicado: (2022)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study
por: Layan, Maylis, et al.
Publicado: (2022)

Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2021)

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study
por: Melzer Cohen, Cheli, et al.
Publicado: (2017)

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents
por: Wu, Qiong, et al.
Publicado: (2023)

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
por: Ishay, Avraham, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Use of Healthcare Services Following Severe Hypoglycemia in Patients with Diabetes: Analysis of Real-World Data
por: Goldstein, Dalit, et al.
Publicado: (2016)

Intravenous Irons: From Basic Science to Clinical Practice
por: Bhandari, Sunil, et al.
Publicado: (2018)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2
por: Ogrič, Manca, et al.
Publicado: (2022)

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
por: Naaber, Paul, et al.
Publicado: (2021)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

The diagnostic potential of the iron-regulatory hormone hepcidin
por: Armitage, Andrew E., et al.
Publicado: (2019)

Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study
por: Shasha, David, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
por: Roca, B, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_737fmbnf3refarfh1886rsrt6i